Suchergebnisse - "Bordoni, Rodolfo"

PubPharm (25)

1

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy

enthalten in: Blood | 2024

von Friedberg, J. | Bordoni, R. | Patel-Donnelly, D. | +8

CommentIn: Blood. 2024 Feb 29;143(9):741-742. - PMID 38421817

2

A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Zeidan, A. | Cook, R. | Bordoni, R. | +7

3

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC : Results From the Randomized Phase 3 IMpower132 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2021

von Nishio, M. | Barlesi, F. | West, H. | +17

CommentIn: J Thorac Oncol. 2021 Apr;16(4):512-514. - PMID 33781439

4

Patient-Reported Outcomes in OAK : A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer

enthalten in: Clinical lung cancer | 2018

von Bordoni, R. | Ciardiello, F. | von Pawel, J. | +9

5

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2018

von Schrock, A. | Pavlick, D. | Klempner, S. | +16

6

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

enthalten in: Blood | 2017

von Friedberg, J. | Forero-Torres, A. | Bordoni, R. | +8

CommentIn: Blood. 2017 Dec 28;130(26):2813-2814. - PMID 29284610

7

Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients

enthalten in: Cancer chemotherapy and pharmacology | 2016

von Madan, A. | Jones, B. | Bordoni, R. | +5

8

Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients

enthalten in: Cancer chemotherapy and pharmacology | 2016

von Madan, A. | Jones, B. | Bordoni, R. | +5

9

Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients

enthalten in: Cancer chemotherapy and pharmacology | 2016

von Madan, A. | Jones, B. | Bordoni, R. | +5

10

Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients

enthalten in: Cancer chemotherapy and pharmacology | 2016

von Madan, A. | Jones, B. | Bordoni, R. | +5